esophageal cancer
Conditions
Interventions
Experimental group:concurrent chemotherapy and mixed radiotherapy (carbon ion plus photon radiation)
Sponsors
Wuwei Tumor Hospital Heavy Ion Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed squamous or adenocarcinoma; 2. AJCC 2017 Eighth Edition cT1-4anyNM0; 3. No distant metastasis to solid organs; 4. Never received any treatment for esophageal cancer; 5. No history of other malignant tumors (except cured skin cancer and stage zero cervical cancer); 6. Renal function, liver function, and bone marrow function are basically normal (serum creatinine 9.5 g/dL; white blood cell count, >= 3000 /ml; platelet count, >= 100,000 /mL); 7. Age greater than 18 and less than 80 years old; 8. Good physical condition, that is, ECOG (Eastern Cooperative Oncology Group) = 6 months; 10. Before radiotherapy, the patient or his legal representative has signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who have already had esophageal and tracheal fistulas or have been judged by doctors to be very likely to have esophageal and tracheal fistulas; 2. Weight loss of more than 20% within six months; 3. During pregnancy (confirmed by serum or urine ß-HCG test) or during lactation; 4. Drug abuse or alcohol dependence; 5. AIDS patients; 6. With uncontrolled systemic, pulmonary or cardiac disease; 7. Accompanied by serious comorbidities that prevent the trial program from being carried out smoothly, including uncontrolled comorbid diseases (insufficient lung function, cardiovascular, lung, liver, kidney, diabetes, etc.), addiction and/or mental illness; 8. Implantation of a pacemaker or other metal prosthesis is enough to affect the progress of radiation therapy; 9. Patients with poor compliance, including those who may not be able to complete the treatment plan, or cannot accept the prescribed follow-up visits and examinations; 10. Have suffered from other malignant tumors (except non-malignant melanoma skin cancer or non-invasive cervical cancer); 11. Receive systemic immunotherapy or corticosteroid therapy at the same time; 12. Serum creatinine clearance < 30 ml/min; 13. Contraindications to radiation therapy; 14. Participated in other drug clinical trials within 30 days before enrollment in this trial; 15. No contraindication capacity for civil conduct radiotherapy or limited capacity for civil conduct; 16. Any medical history that, according to the investigator's judgment, may interfere with the test results or increase the risk of the patient; 17. Any situation that the doctor thinks is not suitable for participating in the trial; 18. The patient refuses to sign the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year local control rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;acute and chronic toxic reactions; | — |
Countries
China
Contacts
Public ContactZhang Yanshan
Wuwei Tumor Hospital Heavy Ion Center
Outcome results
None listed